Literature DB >> 21241733

Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.

Jacqueline E Tate1, Annet Kisakye, Prosper Mugyenyi, Diana Kizza, Amos Odiit, Fiona Braka.   

Abstract

We determined impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children<5 years of age in Uganda from the public health system perspective. Disease-specific models compared the disease burden and cost with and without a vaccination program. If introduced, pneumococcal and rotavirus vaccine programs will save 10,796 and 5265 lives, respectively, prevent 94,071 Streptococcus pneumoniae and 94,729 rotavirus cases in children<5 years, and save 3886 and 996 million Ugandan shillings ($2.3 and $0.6 million US dollars), respectively, in direct medical costs annually. At the GAVI price ($0.15/dose), pneumococcal vaccine will be cost-saving and rotavirus vaccine highly cost-effective. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241733     DOI: 10.1016/j.vaccine.2010.12.122

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Sociocultural determinants of anticipated vaccine acceptance for acute watery diarrhea in early childhood in Katanga Province, Democratic Republic of Congo.

Authors:  Sonja Merten; Christian Schaetti; Cele Manianga; Bruno Lapika; Raymond Hutubessy; Claire-Lise Chaignat; Mitchell Weiss
Journal:  Am J Trop Med Hyg       Date:  2013-07-22       Impact factor: 2.345

Review 3.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

4.  Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan.

Authors:  Lisa M Gargano; Rana Hajjeh; Susan T Cookson
Journal:  Vaccine       Date:  2016-12-15       Impact factor: 3.641

5.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

Review 6.  A critical literature review of health economic evaluations of rotavirus vaccination.

Authors:  Samuel Aballéa; Aurélie Millier; Sibilia Quilici; Stuart Caroll; Stavros Petrou; Mondher Toumi
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

7.  Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.

Authors:  Wilm Quentin; Fern Terris-Prestholt; John Changalucha; Selephina Soteli; W John Edmunds; Raymond Hutubessy; David A Ross; Saidi Kapiga; Richard Hayes; Deborah Watson-Jones
Journal:  BMC Med       Date:  2012-11-13       Impact factor: 8.775

8.  Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.

Authors:  Philip Ayieko; Ulla K Griffiths; Moses Ndiritu; Jennifer Moisi; Isaac K Mugoya; Tatu Kamau; Mike English; J Anthony G Scott
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

Review 9.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.930

10.  Comparison of impact and cost-effectiveness of rotavirus supplementary and routine immunization in a complex humanitarian emergency, Somali case study.

Authors:  Lisa M Gargano; Jacqueline E Tate; Umesh D Parashar; Saad B Omer; Susan T Cookson
Journal:  Confl Health       Date:  2015-02-09       Impact factor: 2.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.